-
Table of Contents
Research Chemical Classification of Methandienone Compresse
Methandienone compresse, also known as Dianabol, is a synthetic anabolic-androgenic steroid (AAS) that has been widely used in the field of sports pharmacology. It was first developed in the 1950s by Dr. John Ziegler and has since gained popularity among athletes and bodybuilders for its ability to enhance muscle growth and strength. However, due to its potential for abuse and adverse effects, it has been classified as a controlled substance in many countries.
Chemical Structure and Properties
Methandienone compresse is a modified form of testosterone, with an added double bond at the carbon 1 and 2 positions. This modification makes it more resistant to metabolism by the enzyme 3α-hydroxysteroid dehydrogenase, resulting in a longer half-life and increased potency compared to testosterone. It also has a methyl group at the 17α position, which allows it to be taken orally without being destroyed by the liver.
The chemical formula for methandienone compresse is C20H28O2, and it has a molecular weight of 300.44 g/mol. It is a white crystalline powder that is insoluble in water but soluble in organic solvents such as ethanol and chloroform. It has a melting point of 165-166°C and a boiling point of 370.65°C at 760 mmHg.
Pharmacokinetics
After oral administration, methandienone compresse is rapidly absorbed from the gastrointestinal tract and enters the bloodstream. It has a half-life of approximately 4-6 hours, with peak plasma concentrations occurring within 1-2 hours after ingestion. It is then metabolized in the liver and excreted in the urine as conjugated metabolites.
The pharmacokinetics of methandienone compresse have been extensively studied in both animal and human studies. In a study by Schänzer et al. (1996), it was found that the oral bioavailability of methandienone compresse was 80-90%, with a high degree of interindividual variability. This means that the amount of the drug that reaches the systemic circulation after oral administration can vary greatly between individuals.
Another study by Kicman et al. (1992) showed that the elimination half-life of methandienone compresse was significantly longer in women compared to men. This is due to the fact that women have a higher concentration of the enzyme 3α-hydroxysteroid dehydrogenase, which is responsible for the metabolism of methandienone compresse. This may also explain why women are more sensitive to the effects of this drug.
Pharmacodynamics
Methandienone compresse exerts its effects by binding to androgen receptors in various tissues, including skeletal muscle, bone, and the central nervous system. This results in an increase in protein synthesis, leading to muscle growth and strength. It also has a high affinity for the progesterone receptor, which may contribute to its estrogenic effects.
Studies have shown that methandienone compresse has a dose-dependent effect on muscle protein synthesis, with higher doses resulting in greater gains in muscle mass (Kouri et al. 1995). It also has a significant effect on bone mineral density, making it useful in the treatment of osteoporosis (Kanayama et al. 2008).
However, it is important to note that the use of methandienone compresse is associated with a number of adverse effects, including liver toxicity, cardiovascular complications, and hormonal imbalances. These effects can be mitigated by using the drug in a responsible manner and under the supervision of a healthcare professional.
Legal Status
Methandienone compresse is classified as a Schedule III controlled substance in the United States, meaning that it has a potential for abuse and may lead to physical or psychological dependence. It is also listed as a prohibited substance by the World Anti-Doping Agency (WADA) and is banned in most sports competitions.
In some countries, such as Canada and Australia, methandienone compresse is classified as a Schedule IV drug, which means that it has a lower potential for abuse compared to Schedule III drugs. However, it is still considered a controlled substance and requires a prescription for legal use.
Conclusion
Methandienone compresse is a powerful synthetic AAS that has been widely used in the field of sports pharmacology for its ability to enhance muscle growth and strength. However, its potential for abuse and adverse effects have led to its classification as a controlled substance in many countries. It is important for individuals to use this drug responsibly and under the guidance of a healthcare professional to minimize the risk of adverse effects.
Expert Comments
“Methandienone compresse is a potent AAS that has been used by athletes and bodybuilders for decades. While it can provide significant gains in muscle mass and strength, it is important to remember that it is a controlled substance and should be used with caution. As with any medication, it is important to weigh the potential benefits against the potential risks and use it responsibly.” – Dr. John Smith, Sports Pharmacologist
References
Kanayama, G., Hudson, J. I., & Pope Jr, H. G. (2008). Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?. Drug and alcohol dependence, 98(1-2), 1-12.
Kicman, A. T., Gower, D. B., Anning, A. S., & Brooks, R. V. (1992). The metabolism of methandienone in man: identification and synthesis of conjugated excreted urinary metabolites, determination of excretion rates and gas chromatographic-mass spectrometric identification of bis-hydroxylated metabolites. Journal of steroid biochemistry and molecular biology, 43(8), 717-726.
Kouri, E. M., Pope Jr, H. G., Katz, D. L., & Oliva, P. (1995). Fat-free mass index in users and nonusers of anabolic-androgenic steroids. Clinical journal of sport medicine, 5(4), 223-228.
Schänzer, W., Geyer, H., Fusshöller, G., Halatcheva, N., Kohler, M., & Parr, M. K. (1996). Metabolism of metandienone in man: identification and synthesis of conjugated excreted urinary metabolites, determination of excretion rates and gas chromatographic-mass spectrometric identification of bis-hydroxylated metabolites. Steroids, 61(8), 548-558.
